An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Yoshioka, Yusuke ^a,b,d   Minoura, Kaho ^c   Takahashi, Ryou u ^a   Takeshita, Fumitaka ^a   Taya, Toshiki ^c   Horii, Reiko ^c   Fukuoka, Yayoi ^c   Kato, Takashi ^b   Kosaka, Nobuyoshi ^a   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c YOKOGAWA ANALYTICAL SYSTEMS INC   (Japan)

^d JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Acgh; Breast cancer; Drug resistance; Gene expression; Microrna

Indexed keywords

MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B; AKT3 PROTEIN, HUMAN; DOCETAXEL; MIRN505 MICRORNA, HUMAN; TAXOID;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ANALYSIS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; METABOLISM; MICROARRAY ANALYSIS; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; TAXOIDS;

EID: 80155151231     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-135     Document Type: Article

References (43)

1. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21. 10.1111/j.1349-7006.2003.tb01345.x, 12708468.
2. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001, 167:3-23. 10.1016/S0300-483X(01)00454-1, 11557126.
3. Renes J, de Vries EG, Jansen PL, Muller M. The (patho)physiological functions of the MRP family. Drug Resist Updat 2000, 3:289-302. 10.1054/drup.2000.0156, 11498397.
4. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003, 10:43-73. 10.1677/erc.0.0100043, 12653670.
5. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355. 10.1038/nature02871, 15372042.
6. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269. 10.1038/nrc1840, 16557279.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
8. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007, 117:2059-2066. 10.1172/JCI32577, 1934569, 17671640.
9. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949. 10.1073/pnas.0506654102, 1236577, 16166262.
10. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008, 27:5204-5213. 10.1038/onc.2008.154, 2562938, 18504438.
11. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101:2999-3004. 10.1073/pnas.0307323101, 365734, 14973191.
12. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-431.
13. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 2008, 14:939-948. 10.1038/nm.1858, 18724378.
14. Lipson D, Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol 2006, 13:215-228. 10.1089/cmb.2006.13.215, 16597236.
15. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. Rna 2007, 13:151-159. 1705746, 17105992.
16. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, Zheng BJ, Lai PB, Lo CM, Chan KW, Guan XY. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707. 10.1016/j.stem.2010.11.010, 21112564.
17. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pébusque MJ, Dusetti NJ. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007, 104:16170-16175. 10.1073/pnas.0703942104, 2042180, 17911264.
18. Ito Y, Motoo Y, Yoshida H, Iovanna JL, Takamura Y, Miya A, Kuma K, Miyauchi A. Decreased expression of tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast carcinoma. Anticancer Res 2006, 26:4391-4395.
19. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833. 10.1038/nature03552, 15944707.
20. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009, 113:3744-3753. 10.1182/blood-2008-09-178707, 2670791, 19096009.
21. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647. 10.1016/j.cell.2005.01.014, 15766527.
22. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123. 10.1016/j.cell.2007.10.054, 18083101.
23. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007, 315:1576-1579. 10.1126/science.1137999, 2556962, 17322030.
24. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008, 68:3429-3439. 10.1158/0008-5472.CAN-07-5867, 2603082, 18451171.
25. Cristiano BE, Chan JC, Hannan KM, Lundie NA, Marmy-Conus NJ, Campbell IG, Phillips WA, Robbie M, Hannan RD, Pearson RB. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res 2006, 66:11718-11725. 10.1158/0008-5472.CAN-06-1968, 17178867.
26. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866. 10.1038/nrc1997, 17060945.
27. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
28. Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002, 21:319-327. 10.1038/sj.onc.1205054, 11803475.
29. Wan X, Yokoyama Y, Shinohara A, Takahashi Y, Tamaya T. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ 2002, 9:414-420. 10.1038/sj.cdd.4400982, 11965494.
30. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD, Tewari M. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008, 27:3880-3888. 10.1038/onc.2008.10, 18264139.
31. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443. 10.1016/j.ccr.2006.04.020, 16766263.
32. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007, 39:673-677. 10.1038/ng2003, 17401365.
33. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922. 10.1038/nature06205, 2748825, 17943132.
34. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997, 15(Spec No):417-474.
35. Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 1999, 18:157-163. 10.1038/sj.onc.1202277, 9926930.
36. Sinha S, Singh RK, Alam N, Roy A, Roychoudhury S, Panda CK. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma. Mol Cancer 2008, 7:84. 10.1186/1476-4598-7-84, 2633285, 18990233.
37. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006, 66:9090-9098. 10.1158/0008-5472.CAN-06-1403, 16982751.
38. Wang Y, Rathinam R, Walch A, Alahari SK. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem 2009, 284:23094-23106. 10.1074/jbc.M109.012617, 2755715, 19546220.
39. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, So CW. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18:606-618.
40. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a Role for Activation of Wnt/{beta}-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. J Biol Chem 286:11009-11020.
41. Senthivinayagam S, Mishra P, Paramasivam SK, Yallapragada S, Chatterjee M, Wong L, Rana A, Rana B. Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. J Biol Chem 2009, 284:13577-13588. 10.1074/jbc.M900248200, 2679459, 19289465.
42. Zhang X, Wang T, Batist G, Tsao MS. Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells. Cancer Res 1994, 54:6122-6128.
43. Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J, Fabregat I. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res 2009, 69:7595-7602. 10.1158/0008-5472.CAN-09-1482, 19773433.